The USbranded generics drive earnings

13 May 2024
5 Min read 
  • Cipla's 4QFY24 results update includes changes in estimates, target price, and rating.
  •  The company reported a slight miss on earnings for 4QFY24 due to higher operating expenses.
  •  Cipla's revenue grew 7.4% YoY, driven by strong traction in the US generics and branded generics segment.
  •  The company's EBITDA margin expanded 90bp YoY to 21.4%.
  •  Cipla plans to launch complex assets in the US and focus on chronic therapies in the domestic segment.
  •  The company's sales in the US grew 21% YoY, and it plans to launch new products in the coming years.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority